|
Date Submitted:
12/11/07
Hits: 18 Rating:  0/5 based on 0 votes
Drug Combo Boosts Multiple Myeloma Survival
Description:
WEDNESDAY, Nov. 21 (HealthDay News) -- A combination drug regimen that includes a derivative of thalidomide extended survival, as well as the time it took for the disease to reappear, in patients with multiple myeloma.
The combination of Revlimid (lenalidomide) and dexamethasone was given U.S. Food and Drug Administration regulatory approval in June of 2006 for multiple myeloma patients who had already failed one treatment. Now, two papers, appearing in the Nov. 22 issue of the New England Journal of Medicine, mark the final publications of the study that paved the way for that approval, said Hildy Dillon, vice president of patient services disease programs at the Leukemia & Lymphoma Society in White Plains, N.Y. "People who got [the combination regimen] had three times the likelihood of responding," added Dr. Donna M. Weber, lead author of the North American segment of the study and associate professor of medicine at M.D. Anderson Cancer Center in Houston. "Overall survival Read the Complete Article Similar content: Hep C Drug Combo for Difficult Cases, in Hepatitis Drug Combo With Antibiotic May Slow MS Progression, in Multiple Sclerosis Multiple Sclerosis Drug Combats Vision Loss, in Multiple Sclerosis Study Compares Stem Cell Transplants for Myeloma, in Leukemia Tomato-Broccoli Combo May Protect Against Prostate Cancer , in Prostate Cancer |
